Aurora Cannabis Inc. (NASDAQ:ACB) Q4 2024 Earnings Conference Call June 20, 2024 8:00 AM ET Company Participants Kevin Niland - Director, Strategic Finance and IR Miguel Martin - CEO Simona King - CFO Conference Call Participants Matt Bottomley - Canaccord Eric Livshits - ATB Capital Markets John Zamparo - CIBC Pablo Zuanic - Zuanic Associates Operator Greetings and welcome to the Aurora Cannabis Inc. Fourth Quarter 2024 Results Conference Call. All participants will be in a listen-only mode and a question- ...

Company Performance - Aurora Cannabis Inc. reported quarterly earnings of $0.11 per share, exceeding the Zacks Consensus Estimate of a loss of $0.18 per share, compared to a loss of $1.50 per share a year ago, indicating a significant improvement [1] - The earnings surprise for this quarter was 161.11%, while the previous quarter saw a loss of $0.20 against an expected loss of $0.10, resulting in a surprise of -100% [1] - The company generated revenues of $49.98 million for the quarter ended March 2024, which was 2.54% below the Zacks Consensus Estimate, but an increase from $47.35 million in the same quarter last year [1] Market Performance - Since the beginning of the year, Aurora Cannabis shares have increased by approximately 20.1%, outperforming the S&P 500's gain of 15% [2] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $61.12 million, and for the current fiscal year, it is -$0.32 on revenues of $230.92 million [4] - The estimate revisions trend for Aurora Cannabis is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the shares are expected to perform in line with the market in the near future [4] Industry Context - The Medical - Products industry, to which Aurora Cannabis belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges for stock performance [5] - Abbott, another company in the same industry, is expected to report quarterly earnings of $1.10 per share, reflecting a year-over-year change of +1.9%, with revenues projected at $10.35 billion, up 3.8% from the previous year [5]

Delivers Record Annual Adjusted EBITDA1 of $12.8 Million NASDAQ | TSX: ACB Q4 Represents the Sixth Consecutive Quarter of Positive Adjusted EBITDA1 Increased Total Quarterly Net Revenue 5% YoY to $67.4 Million, Global Medical Cannabis Net Revenue1 Grew by 20% YoY to $45.6 Million Ended the Fiscal Year with a Cash Position of ~$180 Million with Cannabis Business Debt-Free2 Re-Affirms Target of Reaching Positive Free Cash Flow1 by December 31, 2024 EDMONTON, AB, June 20, 2024 /PRNewswire/ - Aurora Cannabis ...

NASDAQ | TSX: ACB EDMONTON, AB, June 7, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2024 on Thursday, June 20, 2024 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter fiscal year 2024 before the opening of markets th ...

"We are thrilled to bring premium resin cartridges to the Australian market, a signal of our commitment to expanding patient access to an even greater variety of premium cannabis," said Kristin Viccars, Interim Managing Director, MedReleaf Australia. "Our products are designed with the highest standards of quality with safety in mind, and we are confident that Australian patients will value the unique experience our cartridges offer. We continue to look at new opportunities to expand our portfolio and patie ...

Short-squeeze moves can be ferocious and are perfect for investors seeking quick trading gains. With the possibility of a rate cut-induced rally, I am bullish on some short-squeeze stocks for the next few quarters.I am a long-term investor. However, I don’t shy away from taking trading positions in 5% to 10% of my fund allocation towards equities. When there are some clear short-squeeze opportunities, it makes sense to make 50% or 100% gains and invest the profits in long term bets. Of course, the short-squ ...

Group 1: Meme Stock Euphoria - The current market sentiment indicates that meme stock euphoria is in its early stages, with potential rate cuts likely to boost economic growth and trigger a full-fledged meme stock season [1] - A 50% rally in short-squeeze stocks is expected, with the possibility of a 2x or 3x rally in a few months if the meme stock euphoria gains momentum [1] Group 2: Lucid Group (LCID) - Lucid Group's stock has seen a significant downturn, with a correction of nearly 60% over the past year, but it is considered a candidate for a short-squeeze rally [3] - The announcement of a 100% tariff on Chinese-made electric vehicles by Biden could serve as a catalyst for a rally from oversold levels [3] - Lucid has a liquidity buffer of $5 billion, and the management is optimistic about the upcoming launch of Lucid Gravity, which may attract speculative interest [3] Group 3: Aurora Cannabis (ACB) - Aurora Cannabis is identified as having high short interest and is positioned for a potential rally, especially with the upcoming presidential elections where cannabis legalization will be a key topic [5][6] - The company's international medicinal cannabis revenue increased by 41% year-on-year for Q3 2024, indicating healthy revenue growth that could lead to EBITDA margin expansion [6] Group 4: Beyond Meat (BYND) - Beyond Meat's stock has experienced a significant decline, trading in single digits after being near $200 at the end of 2022, yet it remains oversold with short interest above 40% [7] - The company reported a revenue decline of 18% year-on-year to $75.6 million for Q1 2024, along with an adjusted EBITDA loss of $32.9 million, indicating struggles [7] - The launch of the fourth generation of Beyond Burger and Beyond Beef may positively impact financials, and the current oversold levels could trigger a short-squeeze rally [8]

This beaten-down pot stock may have a lot of upside only if the U.S. marijuana market opens up for business.Thus far, 2024 has been an exceptional year for Aurora Cannabis (ACB) stock. Up more than 40%, it's been generating some impressive returns for investors. And recent developments involving rescheduling marijuana in the U.S. has gotten investors even more bullish about the stock and its long-term prospects.Could the Biden Administration's latest move, to reclassify marijuana as a Schedule III substance ...

Among the emerging industries that have captured the attention of investors is the cannabis sector. The cannabis industry has experienced remarkable growth, giving rise to a new breed of top cannabis stocks to buy for investments in May.Although the results so far from the cannabis industry have disappointed many investors, I feel that the long-term prospects remain promising. While the initial hype and optimism surrounding the legalization of cannabis may have led to unrealistic expectations, it is importa ...

NASDAQ | TSX: ACBCanada's Leading Medical Cannabis Company Launches Premium Products Redefining Patient CareEDMONTON, AB, May 8, 2024 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) the Canadian based leading global medical cannabis company, is proud to announce the arrival of Aurora branded medical cannabis products to the New Zealand market. This new line of premium dried flowers represents a significant milestone in medical cannabis accessibility in New Zealand, an emerging market poised for ...